Peter Goes to the Stem Cell Clinic
This video was uploaded from an Android phone.From:Miguel LopezViews:33 1ratingsTime:00:43More inEntertainment
See the original post:
Peter Goes to the Stem Cell Clinic - Video
Hope4Bell -- Donate Today!
Produced by: Luke Skerpon Brandi Wingate My name is Isabella Rinier but everyone calls me Bella. I am now 5 years old. On October 27th, 2009, after being admitted to Penn State Children #39;s Hospital the previous day, I was diagnosed with Neuroblastoma Stage 4. This is a form of childhood cancer found mainly in the bone marrow. I went through 6 months of chemotherapy, and a major surgery to remove the tumor that was found on my left kidney. In May 2010 I had a bone marrow transplant. I was doing wonderful until one day mommy and daddy noticed i was walking funny. On February 14th, 2011, my family found out that I had relapsed. This time the doctors found 6 major tumors on my brain. The doctors told my mommy and daddy that i only had 3-6 months to live. I was placed in ICU to get the pressure off my brain and to start treatment right away. I am now under a new experimental treatment that is being conducted at Penn State Children #39;s Hospital Stem Cell Clinic. I am doing well and thanks to God, I only have 2 Tumors that at this time show up on my MRI scans.. I #39;m winning this battle one day at a time.From:lskerponViews:333 0ratingsTime:01:03More inPeople Blogs
Read more here:
Hope4Bell -- Donate Today! - Video
Liza #39;s MS Cure - Please DONATE for her treatment
We are raising funds to send Liza, a mother of two little girls, to the Stem Cell Institute in Panama to receive stem cell treatment for her multiple sclerosis. Please make a donation at http://www.youcaring.com MS is a debilitating disease, and the stem cell clinic is having a lot of success treating it. Liza is a good candidate for total recovery.From:scottsdalemmViews:55 0ratingsTime:03:27More inNonprofits Activism
Read more from the original source:
Liza's MS Cure - Please DONATE for her treatment - Video
Two Medical Mistakes, Japan Police Wont help Foreign child,..For My Son Jimmy .wmv
This Video is one day after a doctor from a Military hospital in Japan heavily sedated my son with the same strong anesthetic drugs used to death penalty and placed a plastic bag over his head without parents signed inform consent--he was going to torture my son. He suffered major brain injury and was considered bain dead. We called the Japan Police and they informed hospital and evidense was tampered with and destroyed. Just before this attempted muder on our son we were in final stages to opening a stem cell clinic in the New Otani Hotel, My wife and I were targeted and Japan police will not help us. We have tape recorded conversations with Japan police making threats that they can make any problems for us big at anytime and also talephone conversations of Japan Doctor confessing to putting a plastic bag over our sons head after false statement claiming he did not. My son is kept alive by a life support machine. My wife and I have been targetedFrom:James RyanViews:97 1ratingsTime:00:54More inNonprofits Activism
See the article here:
Two Medical Mistakes, Japan Police Wont help Foreign child,..For My Son Jimmy .wmv - Video
German AIDS Cure With Stem Cells Now Licensed to Thai Stem Cell Clinic
youtu.be As differentiated or undifferentiated, whether from sheep stem cells or from rabbit; delivered frozen or fresh, today #39;s stem cell therapies are showing real promise and helping HIV-AIDS sufferers around the world, today! Cautious not to claim they can cure ANYTHING, today #39;s ethical clinics offer hope for AIDS-HIV sufferers worldwide, although the one Thai clinic licensed by the German stem cell technique is in Bangkok. For information to help you make an informed, personal decision, visit StemCell-Asia.info today.From:Kerry DeanViews:1 0ratingsTime:01:08More inScience Technology
Go here to see the original:
German AIDS Cure With Stem Cells Now Licensed to Thai Stem Cell Clinic - Video
SOUTH SAN FRANCISCO, CA--(Marketwire - Oct 16, 2012) - VistaGen Therapeutics, Inc. ( OTCBB : VSTA ) ( OTCQB : VSTA ), a biotechnology company applying stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and liver toxicology and drug metabolism screening, today announced the completion of the previously announced $3.25 million financing commitment with Platinum Long Term Growth VII, LLC (Platinum) and approximately $3.0 million strategic debt restructuring. The combined transactions involve the Company's three largest institutional shareholders and its patent counsel.
"Today marks a significant turning point for VistaGen. These transactions represent a tremendous vote of confidence by four of our major stakeholders and position us to realize the full measure of our commercial opportunities involving our stem cell technology platform and AV-101 clinical program," said Shawn K. Singh, VistaGen's Chief Executive Officer.
"Our expectations are set very high. Over the next 12 months, we plan to achieve multiple transformative milestones, both in the lab and in the clinic. This funding provided by Platinum, combined with our strategic equity-based restructuring transactions with Cato Research, Morrison & Foerster and University Health Network, will be instrumental in our success," concluded Mr. Singh.
Allen Cato, M.D., Ph.D., co-founder and Chief Executive Officer of Cato Research, stated, "By more closely approximating human biology, VistaGen's stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development. We are pleased to support VistaGen's efforts to transform the drug development process and to bring safer, more effective therapies to market."
Michael Goldberg, M.D., Portfolio Manager of Platinum Long Term Growth VII, commented, "VistaGen has been, and continues to represent, an excellent investment opportunity for Platinum. Our continued commitment toward supporting VistaGen underscores our confidence in the Company's novel stem cell technologies and AV-101."
Further information regarding the Company's recent financing transaction with Platinum Long Term Growth Fund, and its strategic debt restructuring transactions with Cato Research, Morrison & Foerster and University Health Network, is set forth in the Company's Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission (SEC) and available on both the SEC's website at http://www.sec.gov and the Company's website at http://www.VistaGen.com.
About VistaGen Therapeutics
VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and liver toxicology and drug metabolism screening. VistaGen's drug rescue activities are focused on combining its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube, with modern medicinal chemistry to generate new chemical variants (Drug Rescue Variants) of once-promising small-molecule drug candidates. These are drug candidates discontinued due to heart or liver toxicity after substantial investment and development by large pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.
Additionally, VistaGen's orally-available, small molecule drug candidate, AV-101, is completing Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.
Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen.
See the rest here:
VistaGen Therapeutics Completes $3.25 Million Financing and $3.0 Million Debt Restructuring
Last year, Kyoto University in Japan, managed to create eggs and sperm in mice that were successfully fertilized through to baby mice being born. Now an American research team are stepping up their attempts to produce human sperm using stem cells.
London, UK (PRWEB UK) 12 October 2012
The inability to conceive a baby can have many reasons which affect either the female or male or both, that are involved in creating an offspring. Where actual fertility is concerned there are stages throughout a woman and a mans life when their ability to conceive easily occurs. The younger you are when you attempt to have children, the better. With a lot of couples establishing their careers and leaving it till later to start a family, there is bound to be more couples that will require investigating, which leads to fertility treatment.
Worry involved with infertility can cause other side effects, such as erectile dysfunction and stress can be a key factor in ED. Viagra or Cialis are good treatments for this possibly temporary problem.
This research is highly controversial as it uses embryonic stem cells because they provide the best start. Stem cells are part of multicellular organisms that via mitosis can form any cell type. This makes them so versatile when used to grow cells for bone marrow, body organs, repairing nerves or actually any cell in the human body.
There has always been objections to this medical research as cells are harvested from embryos. Dr Reijo Pera obtains the stem cells from the extra eggs that are not needed after IVF treatments. IVF clinics in America make 1 to 1.5 million ova a year and of these, 500,000 are disposed of. Seemingly many are concerned over the 500 being used to enhanced medical procedures and the health of the overall population, instead of the yearly disposal of 500,000 eggs that could be used in lifesaving treatment.
With the ground breaking achievements made by Japanese scientists in making baby mice from sperm and eggs that were grow with stem cells, it has given the US team a boost for their studies to go to the next stage and create a human baby in this way. Being able to produce a viable fertilised egg to be implanted by this method would help so many childless couples. Also the implications as to extending the length of childbearing years of women could be of benefit for those postponing parenthood.
All this said there are factors of opposition to stem cells being used and should women be able to have a baby in later years. So who is going to be brave enough to allow general use of stem cells recovered from embryos and decide how old is too old for a woman to give birth.
Written by Frances Cerulean
Article Source : http://www.uk-med.co.uk/Health/Laboratory-Sperm-Creation-Available-Within-Two-Years
Public release date: 3-Oct-2012 [ | E-mail | Share ]
Contact: Claire Gwayi-Chore cgwayi-chore@hematology.org 202-776-0544 American Society of Hematology
(WASHINGTON, October 3, 2012) New research appearing online today in Blood, the Journal of the American Society of Hematology (ASH), suggests that long-term survivors of hematopoietic cell transplants (HCT) are at an increased risk of developing heart disease risk factors such as high blood pressure, diabetes, and high cholesterol when compared to the general population. These risk factors, combined with exposure to pre-HCT therapy, contribute to a noticeably increased risk of heart disease over time.
HCT, the transplantation of blood-forming stem cells from the bone marrow, circulating blood, or umbilical cord blood, is the primary treatment option for many patients with blood disorders. The healthy transplanted stem cells replace patients' damaged cells that caused their illness. Advances in transplantation strategies have contributed to marked improvements in patient outcomes, resulting in a growing number of long-term transplant survivors, many of whom struggle with one or more chronic, post-transplant health conditions. Previous researchers have speculated that survivors' exposure to potentially heart damaging pre-transplant chemotherapy and radiation or treatment for a life-threatening transplant complication known as graft-versus-host-disease (GVHD) can increase their risk of developing heart disease and its associated risk factors. However, there have been limited data to validate the contribution of pre-conditioning chemotherapy or radiation and GVHD to the eventual development of heart disease in long-term HCT survivors.
"While we know that heart disease is a real concern for long-term HCT survivors, small sample sizes and a lack of long-term follow up in previous studies have only allowed us to look at a small piece of the puzzle of how this chronic condition develops in these patients," said Saro H. Armenian, DO, MPH, the study's first author, Assistant Professor in the Division of Outcomes Research, and Medical Director of the Pediatric Survivorship Clinic in the Childhood Cancer Survivorship Program at City of Hope in Duarte, CA. "Our study sought to better determine the specific factors before and after transplant that can lead to heart disease in a large group of transplant recipients."
In order to more thoroughly evaluate heart disease risk and development in HCT recipients, Dr. Armenian and his team of researchers designed a retrospective study to evaluate factors that may affect a survivor's risk of developing high blood pressure, diabetes, and high cholesterol after HCT. These factors included transplant recipients' exposure to pre-transplant chemotherapy and radiation, conditioning therapy for HCT, their type of HCT transplant, and whether they developed and were treated for GVHD post transplant.
To better determine HCT survivors' incidence of high blood pressure, diabetes, and high cholesterol compared to the general population, researchers analyzed medical records of 1,885 patients who underwent a first-time HCT for a blood cancer at City of Hope between 1995 and 2004 and had survived at least one year. The National Health and Nutrition Examination Survey was used to generate expected heart disease risk factor rates for the general population.
Following their analysis, researchers found a higher prevalence of high blood pressure, diabetes, and high cholesterol in long-term HCT transplant survivors when compared to the general population. HCT conditioning with total body radiation was associated with a 1.5-fold increase in risk of developing diabetes and a 1.4-fold increase in risk of developing high cholesterol, regardless of HCT type, a finding that validates previous reports from long-term childhood and adult HCT survivors. While the mechanism by which total body radiation increases the risk of diabetes and high cholesterol in HCT recipients is not clear, previous studies have shown that abdominal radiation may contribute to known heart disease risk factors such as insulin resistance and an increase in belly fat in conventionally treated cancer patients. This evidence suggests that radiation-induced pancreatic or liver injury may play a role in an HCT transplant survivor's development of heart disease by increasing their risk for heart disease risk factors.
Next, researchers assessed the role of transplant type on long-term HCT survivors' risk of developing key heart disease risk factors. After reviewing the data, researchers observed that those who had received transplanted stem cells from a donor (allogeneic HCT) were at a significantly higher risk of developing high blood pressure, diabetes, or high cholesterol after transplant than those who had received blood-forming stem cells from their own body (autologous HCT). Over the 10-year study period, 45.3 percent of allogeneic HCT recipients developed high blood pressure, 20.9 percent developed diabetes, and 50.5 percent developed high cholesterol; whereas only 32 percent, 15.9 percent, and 43.3 percent of autologous HCT recipients developed these same conditions, respectively. Transplant recipients who had undergone an allogeneic HCT and who had experienced GVHD had the highest risk of developing heart disease risk factors, researchers concluded; 54.7 percent of this group developed high blood pressure, 25.8 percent developed diabetes, and 52.8 percent developed high cholesterol.
Not only did more allogeneic than autologous HCT recipients develop these heart disease risk factors over this time period, but they also developed them more quickly. Allogeneic HCT recipients developed high blood pressure and high cholesterol both at a median time to onset of 2.5 months, compared with autologous HCT recipients who developed the same conditions at 3.7 years and 1.6 years, respectively. Allogeneic HCT recipients also developed diabetes more than two years earlier than autologous recipients (1.2 year median time to onset for allogeneic HCT recipients vs. 3.3 years for autologous transplant recipients).
Read the original:
Study suggests stem cell transplant survivors at increased risk of developing heart disease
Public release date: 3-Oct-2012 [ | E-mail | Share ]
Contact: Garth Sundem garth.sundem@ucdenver.edu University of Colorado Denver
The University of Colorado Cancer Center, together with other participating academic medical centers, recently opened a phase I human clinical trial of the drug OMP-54F28 in patients with advanced solid tumor cancers. OMP-54F28, a candidate investigational drug discovered by OncoMed Pharmaceuticals, targets cancer stem cells (CSCs), also known as tumor-initiating cells, which many researchers believe are at the root of tumor occurrence and growth. These CSCs are notoriously resistant to existing chemotherapies and so may survive current treatments to repopulate a tumor, leading to relapse and metastasis.
"It's a terrific opportunity to put a drug targeting cancer stem cells in the clinic, especially a drug with as much promise in preclinical studies as this one," says Antonio Jimeno, MD, PhD, investigator at the CU Cancer Center, director of the university's Cancer Stem Cell-Directed Clinical Trials Program, and principal investigator of the clinical trial at the CU Cancer Center site. "It is a privilege to work with such a science-focused partner, whose vision totally aligns with ours: bringing to the clinic cutting-edge drugs and ideas that are supported by robust scientific data. In the context of the collaboration between the Gates Center for Stem Cell Biology and the CU Cancer Center this will be the second clinical trial we will be offering to our patients with the specific intent to target the CSCs in their tumors."
Specifically, OMP-54F28 is an antagonist of the Wnt pathway, a key CSC signaling pathway that regulates the fate of these cells. The Wnt pathway has been intensively studied and is now known to be inappropriately activated in many major tumor types, including colon, breast, liver, lung and pancreatic cancers, and is thought to be critical for the function of CSCs. Because of this extensive preclinical validation, the Wnt pathway has been a major focus of anti-cancer drug discovery efforts. OMP-54F28 and a sister compound also developed by OncoMed, OMP-18R5, are believed to be two of the first therapeutic agents targeting this key pathway to enter clinical testing. Both OMP-54F28 and OMP-18R5 are part of OncoMed's Wnt pathway strategic alliance with Bayer Pharma AG.
In multiple preclinical models, OMP-54F28 has shown its effectiveness in reducing CSC populations, leading to associated anti-tumor activity, either as a single agent or when combined with chemotherapy.
The Phase I clinical trial of OMP-54F28 is an open-label dose escalation study in patients with advanced solid tumors for which there is no remaining standard curative therapy. These patients are assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and initial signals of efficacy. The trial is being conducted at Pinnacle Oncology Hematology in Scottsdale, Arizona, the University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, and the CU Cancer Center under the direction of Principal Investigators Dr. Michael S. Gordon, Dr. David Smith and Dr. Antonio Jimeno, respectively.
"We all hope and expect this drug to live up to its preclinical potential," Jimeno says. "And if it does, we will have a powerful new therapy, exploiting a novel pathway to target this most dangerous subpopulation of cancer cells."
###
About OncoMed Pharmaceuticals
Read more:
CU Cancer Center opens phase i clinical trial of anti-cancer stem cell agent OMP-54F28
OCEANSIDE, Calif., Oct. 1, 2012 /PRNewswire/ --Health Link Medical Center, a national leader in regenerative interventional orthopedics and advanced biological cell therapies, today announced the planned opening of their new location in Mill Valley, California in October 2012. Health Link Medical Center's Oceanside, California clinic is currently California's only provider of Regenexx orthopedic platelet and autologous stem cell procedures.
Regenexx Procedures offer non-surgical treatment options for common joint injuries and degenerative conditions, such as osteoarthritis. The procedures utilize a patient's own stem cells to help heal damaged tissues, tendons, ligaments, bone, or cartilage. Regenexx patients experience less downtime and avoid the lengthy and painful rehabilitation periods that follow surgery.
"We're excited for the opportunity to bring Regenexx Procedures to the San Francisco area," said Dr. Norman Deitch, CEO of Health Link Medical Center. "Patients regularly travel across the country for the opportunity to receive these leading non-surgical treatments. This expansion makes them conveniently accessible to the millions of individuals in northern California."
The Mill Valley Center will include a biological cell laboratory, capable of the advanced laboratory processing of platelets and stem cells required for the same-day procedures. Paul Handleman, D.O., has joined Health Link with an extensive interventional orthopedic background and has been in practice in Marin County, California for more than 15 years. Dr. Handleman has undergone advanced training at the Regenexx / Centeno-Schultz home clinic in Broomfield, Colorado.
Regenexx Procedures are currently performed at Health Link's Oceanside, CA. location. The Mill Valley Center opening is slated for October 2012 and Health Link is already scheduling patients for the new location. For more information, visit http://www.healthlinkcenter.com or call 800-281-3757.
About Health Link Medical Center
Based in Oceanside, California, Health Link Medical Center is a leader in regenerative interventional orthopedics and advanced biological cell therapies. Health Link is California's first provider of Regenexx Stem Cell and Blood Platelet Procedures. Learn more at http://www.healthlinkcenter.com.
About Regenexx and the Regenexx Physician Network
Regenexx Procedures offer non-surgical treatments for joint injuries and degenerative conditions. For more information on Regenexx Procedures and the Regenexx Physician Network, visit: http://www.regenexx.com
Contact:
See the rest here:
Health Link Medical Center Introduces the Regenexx™ Orthopedic Stem Cell Treatments to the San Francisco Area